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Abstract: Central nervous system (CNS) drug disposition is dictated by a drug’s 
physicochemical properties and its ability to permeate physiological barriers.  
The blood–brain barrier (BBB), blood-cerebrospinal fluid barrier and centrally located 
drug transporter proteins influence drug disposition within the central nervous system. 
Attainment of adequate brain-to-plasma and cerebrospinal fluid-to-plasma partitioning is 
important in determining the efficacy of centrally acting therapeutics. We have developed a 
physiologically-based pharmacokinetic model of the rat CNS which incorporates brain 
interstitial fluid (ISF), choroidal epithelial and total cerebrospinal fluid (CSF) 
compartments and accurately predicts CNS pharmacokinetics. The model yielded 
reasonable predictions of unbound brain-to-plasma partition ratio (Kpuu,brain) and 
CSF:plasma ratio (CSF:Plasmau) using a series of in vitro permeability and unbound 
fraction parameters. When using in vitro permeability data obtained from L-mdr1a cells to 
estimate rat in vivo permeability, the model successfully predicted, to within 4-fold, 
Kpuu,brain and CSF:Plasmau for 81.5% of compounds simulated. The model presented 
allows for simultaneous simulation and analysis of both brain biophase and CSF to 
accurately predict CNS pharmacokinetics from preclinical drug parameters routinely 
available during discovery and development pathways. 
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1. Introduction  
Quantification of central nervous system (CNS) drug levels in brain interstitial fluid (ISF) and 
cerebrospinal fluid (CSF) is often achieved by complex in vivo experimental procedures, such as 
microdialysis. This technique has the inherent advantage of directly measuring the concentration of 
unbound drug in the accessible brain biophase under non-steady state and steady-state conditions [1,2], 
reflecting both drug influx and efflux processes acting within the CNS. To be able to quantify the brain 
pharmacokinetics of a compound of interest, microdialysis offers the advantage of multiple time-point 
sampling within the same animal, although the procedure leads to local tissue damage around the site 
of probe insertion [3,4] and is an experimental procedure often limited to lower-species, although 
neuroimaging techniques, such as positron emission tomography, have been utilised in both lower- and 
higher-species to quantify temporal drug concentrations in brain [5]. Microdialysis and PET  
(positron emission tomography) are often considered the “gold-standard” for assessing (regional) brain 
disposition of drugs, but can be limiting due to their technical and experimental complexity, which 
may hinder widespread use in pre-clinical studies. 
The ability to determine the relationship between systemic exposure and CNS drug disposition is an 
important focus for pharmaceutical industry and drug development programs. Typically, pre-clinical 
measurement of drug partitioning between the CNS (brain tissue and CSF components) and plasma to 
yield total brain-to-plasma concentration ratio, Kpbrain is conducted in rodents and Kpbrain is then 
converted to the unbound concentration ratio (Kpuu,brain) by multiplication with plasma unbound drug 
fraction (fup) (Equation (1) C, total concentration; Cu, unbound concentration; Vu, unbound brain volume of 
distribution) [6]. The steady-state unbound brain-to-plasma ratio (Kpuu,brain) (Equation (2)) or steady-state 
cerebrospinal fluid-to-plasma concentration ratios (CSFu:Plasmau and CSF:Plasmau) (Equations (3) 
and (4) respectively) are routinely used to represent CNS disposition of pharmacologically active 
drugs within the CNS.  
Kpbrain=
Cbrain
Cplasma
 and Kpuu,brain=
Kpbrain
Vubrain × fup
 (1)
Kpuu,brain=
׬ Cubrain × dt∞0
׬ Cuplasma × dt∞0
=
AUCu,brain
AUCu,plasma
 (2)
CSFu:Plasmau=
׬ Cucsf × dt∞0
׬ Cuplasma × dt∞0
=
AUCu,csf
AUCu,plasma
 (3)
CSF:Plasmau=
׬ Ccsf × dt∞0
׬ Cuplasma × dt∞0
=
AUCcsf
AUCu,plasma
 (4)
Kpuu,brain and CSFu:Plasmau values less than 1 typically indicate restricted entry into the brain or 
CSF-compartments, predominantly a result of efflux or uptake transport proteins respectively, whereas 
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values greater than 1 indicate unrestricted entry into the brain or CSF, facilitated by active transport. 
Values close to unity indicate predominantly passive transport of drug. 
A major factor in successful delivery of drugs to the CNS is circumvention of physiological 
barriers. The ATP-binding Cassette (ABC) efflux transporters P-glycoprotein [7], breast cancer 
resistance protein (BCRP) and several multidrug resistance-associated proteins (MRPs) are expressed 
at the BBB (blood–brain barrier) [7–10]. Mdr1 knockout studies in mice reveal that P-glycoprotein 
significantly influences CNS disposition of both non-CNS targeted and CNS targeted therapeutics 
including amitriptyline, nortriptyline [11], olanzipine [12], buspirone, chlorpromazine, fluvoxamine, 
risperidone, zolpidem [13] and fexofenadine [14]. Similar reports of altered brain penetration of 
imatinib [15], oseltamivir [16] and genistein [17] have been reported in breast cancer resistance protein 
knockout mice. In addition to BBB-associated ABC transporters influencing CNS drug disposition, 
expression of highly restrictive tight junction complexes at the BBB (the transcellular electrical 
resistance is reported to be between 1000 and 1800 Ω cm2 [18–20]) results in only limited passive 
diffusion of hydrophilic, low molecular weight (<400 Da) compounds [21] across the BBB into the CNS. 
The blood-cerebrospinal fluid barrier (BCSFB) also can regulate entry of compounds into the  
CNS [22] and is an important consideration when describing CNS drug disposition. The BCSFB is 
located next to the choroidal epithelium, a continuous single layer of polarized epithelial-like cells, 
possessing tight junctions [23], which line the surface of the choroid plexuses. There are important 
physiological differences between the BBB and BCSFB. In vitro measurements suggest the 
transcellular electrical resistance of the BCSFB is approximately 10- to 15-fold less than that of the 
BBB, at 80–100 Ω cm2 [18–20]. Unlike the BBB, the choroidal epithelium possesses extensive 
microvilli and studies suggest the total surface area of the choroid plexuses may be 10-fold greater 
than previous estimates, placing the surface area within a similar order of magnitude to that of the 
BBB [24–28], and resulting in in vivo BCSFB clearance measurements, per gram of brain, which may 
be similar to or greater than that at the BBB [29]. However, both P-glycoprotein [30,31] and BCRP [31] 
have been reported to be expressed at the apical plasma membrane of the choroidal epithelium, and 
have the potential to transport drugs from the choroidal epithelium into the ventricular CSF. It is 
therefore important that the differential transport directionalities at the BBB and BCSFB sites are taken 
into consideration when attempting to predict drug disposition within the CNS. 
Efflux transporter proteins at the BBB will therefore limit penetration of compounds into the brain 
and impact on CNS disposition, whereas efflux transports at the BCSFB will act to potentially enhance 
the accumulation of compounds in the CSF. Consequently, for highly effluxed drugs there is often a 
discrepancy between the effects of efflux at the BBB (influencing Kpuu,brain) and the BCSFB 
(influencing CSFu:Plasmau) [32–34]. 
Clearly, the measurement of brain unbound concentrations would provide a better indicator for 
assessing CNS disposition, but microdialysis is not an option routinely employed, pre-clinically. 
However, determination of the extent of non-specific brain tissue binding (fubrain), using brain slice and 
brain homogenate methods, is utilised to drive forward an understanding of overall brain drug 
penetration. Thus, an understanding of the role of drug transporter proteins at both the BBB and 
BCSFB coupled with knowledge of brain tissue binding is crucial in order to more effectively predict 
CNS drug disposition (Kpuu,brain and CSFu:Plasmau) and facilitate early pharmacokinetic predictions 
and selection of compounds for further development [13,35]. 
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A key paradigm in CNS drug development is the prediction of brain accumulation of candidate 
compounds [36,37]. The application of physiologically-based pharmacokinetic modeling provides an 
approach to mechanistically incorporate routinely determined in vitro data, such as drug permeability 
and protein binding, into a pharmacokinetic model capable of estimating CNS drug disposition. There 
is, however, a significant lack of predictive models capable of quantifying CNS drug disposition.  
In non-physiological models, the CNS is described by either a 1-compartment model (representing 
brain) or a 2-compartment model (representing brain interstitial fluid and brain intravascular fluid 
(IVF)) with such models often being used in conjunction with brain microdialysis data to describe 
CNS drug disposition [2,3]. Semi-physiological models have also been proposed that attempt to 
mechanistically describe drug disposition within the brain [38–42] but are nonetheless hindered by the 
requirement for some a priori clinically-derived input data. 
Recently Ball et al. [43] described the development of a whole-body physiologically based 
pharmacokinetic (PBPK) model for the prediction of unbound drug concentration-time profiles in the 
rat brain, utilising a mechanistic approach to described drug transfer across the blood–brain barrier. 
Despite this, there is a lack of fully mechanistic CNS PBPK models employed to describe CNS 
pharmacokinetics, which limits the application of such models to the prediction of CNS drug disposition. 
A key challenge in predicting CNS drug disposition is the extrapolation of cell line-derived 
permeability data obtained in vitro to an in vivo permeability metric. In vitro permeability data derived 
from immortalised non-cerebral and cerebral cell lines [44–49] has been used previously to assess 
BBB penetration [50–52] despite clear phenotypic differences (e.g., efflux transporter expression 
profile, enzyme activity) between many of the cell lines used, e.g., Caco-2 (human colorectal 
adenocarcinoma cell line) and MDCK (Madin-Darby canine kidney cells), and blood–brain barrier 
endothelial cells. 
Recently, positive correlations between drug permeability assessed in the L-mdr1a cell line (the 
LLC-PK1 porcine kidney cell line transfected with murine P-glycoprotein) and the extent of CNS drug 
disposition (Kpbrain) have been reported [53–55]. Of fundamental importance to this correlation is  
P-glycoprotein protein abundance in transfected cell lines compared to brain microvascular endothelial 
cells within the BBB. Recent progress in the quantification of absolute expression levels of  
P-glycoprotein in brain capillaries has estimated total mdr1a protein abundance in mouse brain 
capillaries to be 14.1 fmol/μg protein [56] and rat brain capillaries to be 19.1 fmol/μg protein [57] 
which is very similar to the in vitro protein abundance in L-mdr1a cells, 15.2 fmol/μg protein [54,55], 
but higher in comparison to that measured in human brain capillaries (6.06 fmol/μg protein) [54].  
Such findings suggest data derived from L-mdr1a cells could be incorporated into predictive 
physiologically-based pharmacokinetic models and may prove useful in assessing CNS drug disposition 
for P-glycoprotein substrates. 
In the present study we describe a predictive, physiologically-based pharmacokinetic model of the 
rat CNS which incorporates discrete brain and CSF components and is able to predict brain-to-plasma 
and CSF-to-plasma ratios using in vitro permeability parameters and drug protein/tissue binding data. 
In addition, we also developed a mouse whole-body PBPK model which, when populated with mouse 
physiological parameters and L-mdr1a cell-derived data, allowed prediction of mouse Kpuu,brain and 
CSF:Plasmau (see Supplementary Information). 
Pharmaceutics 2014, 6 101 
 
2. Experimental Section  
2.1. Development of a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model 
2.1.1. Model Development 
A whole-body PBPK model was constructed in Matlab (version 8.1). The model consisted of the 
following compartments: lung, bone, brain vascular space (V), brain extravascular space (EV), 
cerebrospinal fluid (CSF), choroid plexus (CP), heart, kidney, liver, muscle, adipose, skin, pancreas, 
gut, spleen, and arterial and venous blood (Figure 1). All tissue compartments were considered well 
stirred (perfusion limited) except for CNS-related compartments (Figure 1).  
Figure 1. (A) Whole-body physiologically based pharmacokinetic (PBPK) model.  
CL: Clearance; CSF: Cerebrospinal fluid; and (B) Brain and CSF compartments.  
V: vascular compartment; EV: extra-vascular compartment; CLpassive: passive clearance; 
CLactive: active efflux clearance. 
 
Mouse and rat tissue volumes and perfusion rates were sourced from literature sources [58] (Table 1) 
with drug tissue partition coefficients calculated from the tissue-composition-based approach [59,60] 
using LogP and pKa parameters predicted using ChemAxon (http://www.chemaxon.com) or  
obtained from the literature (see Supplementary Information). Where absent in the literature, blood 
flow was scaled based on an allometric function (weight3/4), and tissue volumes scaled to  
body weight [61,62], assuming a mouse body weight of 30 g and rat body weight of 250 g [58]  
(see Supplementary Information). 
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Table 1. Physiologically based pharmacokinetic (PBPK) model parameters for rats and mice. 
Tissue 
Rat a Mice b 
Blood flow Tissue volume Blood flow Tissue volume 
(mL/h) (mL) (mL/h) (mL) 
Arterial blood 2580 5.6 839.0 0.40 
Venous blood 2580 11.3 839.0 0.81 
Lung 2580 1.6 839.0 0.12 
Liver (Total) 120 10.3 16.8 0.74 
Hepatic artery c 0.29 - 0.28 - 
Portal vein d 2.12 - 1.96 - 
Kidney 553 2.3 91.9 0.17 
Stomach 8 1.1 4.8 0.08 
Spleen 37.8 0.6 9.5 0.04 
Pancreas 30 1.3 2.2 0.09 
Intestine 451 11 117.0 0.79 
Muscle 450 122 133.0 8.79 
Adipose 24 10 59.0 0.72 
Skin 350 40 48.4 2.88 
Bone 75.9 15.8 92.3 1.14 
Heart 236 0.8 55.1 0.06 
Thymus 18 0.7 1.4 0.05 
Brain e 120 f 1.8 25.9 g 0.36 
Brain IVS h - 0.025 - 0.005 
Brain ISF - 0.33 - 0.067 
ISF bulk flow 0.03 i - 0.0016 - 
CP j - 0.0036 - 0.00072 
CSF 80 1.2 25.8 0.09 
a Taken from Brown et al. [58]; b taken from Brown et al. [58] or blood flow scaled to the 0.75 of body 
weight and tissue volumes scaled to body weight (bold) [61,62]; c assuming hepatic artery flow is 2% 
(mouse) and 2.1% (rat) of cardiac output [58]; d assuming portal vein flow is 14.1% (mouse) and 15.3% (rat) 
of cardiac output [58]; e fractional volume of brain intravascular fluid, 0.014; Fractional volume of brain 
interstitial space, 0.188 [63], assuming brain weight of 1.8 g in rats and 0.36 g in mice [64]; f average of 
values reported from Eyal et al. [65] and Stange et al. [66]; g taken from Jay et al. [67]; h Brain IVS: brain 
intravascular space; i taken from Abbott et al. [68]; and j assuming choroid plexus (CP) weight is 0.2% of 
brain weight [69]. 
The CNS was comprised of brain IVS (intravascular space), brain ISF and CSF compartments.  
A rate-limited permeability barrier between the IVS and ISF and IVS and CSF represented the BBB 
and BCSFB respectively, and was incorporated into the model as passive bi-directional clearance 
terms (CLpassive) and active efflux terms (CLactive) modeling both passive and active flux of compounds 
across each permeability barrier (Figure 1). Bulk flow of ISF was incorporated within the model to 
represent the flow of unbound brain ISF drug to CSF. Unbound drug fractions in plasma (fup), brain 
ISF (fub) and cerebrospinal fluid (fuCSF) were incorporated into the plasma, brain and CSF 
compartments respectively. 
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Well-stirred organs were described by the following equation: 
dCt
dt
=
Qt
Vt
×Cart-
Qt
Kpt×Vt
×Ct (5)
where C is the concentration of drug, Qt is the tissue perfusion rate, Cart is the arterial drug input,  
Vt is the volume of tissue compartment and Kpt is the partition coefficient of the tissue compartment. 
The removal of drugs from the eliminating organs (liver and kidney) was described by additional 
clearance terms (hepatic clearance: CLH and renal clearance: CLR). Hepatic clearance was predicted from 
in vivo data (human blood or plasma clearance: CLb or CLp) or in vitro data (in vitro intrinsic metabolic 
clearance: CLint, in vitro) and renal clearance was calculated using a GFR (glomerular filtration rate) 
correction approach [70]. 
When using CLb or CLp as an input, the in vivo intrinsic clearance (CLint, in vivo) was calculated 
(Equation (6)) by, if necessary, correcting for the blood:plasma ratio (Rb) (Equation (7)) (or, where not 
available, by assuming Rb = 1 for basic drugs and Rb = 0.55 for neutral and acidic drugs), and scaled 
using an allometric function of body weight (weight3/4) to yield a species-specific CLint, in vivo. 
CLint, in vivo = 
CLb
fub× ൬1- CLbQH ൰
 (6)
fub= 
fup
Rb
 (7)
When using the in vitro intrinsic metabolic clearance (CLint, in vitro) as input, an in vivo intrinsic 
clearance (CLint, in vivo) term was calculated by scaling CLint, in vitro accounting for microsomal  
recovery (microsomal protein content (rat: 45 milligrams protein per gram of liver [71] or hepatocellularity  
130 × 106 cells per gram of liver) [72,73] and rat or mouse liver weight (40 grams per kilogram body 
weight [58] and 88 grams per kilogram body weight [71] respectively. 
The unbound hepatic plasma clearance was then calculated using a well-stirred liver model 
(Equation (8)), where hepatic blood flow (Qh) was assumed to be 55 mL min−1 kg−1 (rats) and  
90 mL min−1 kg−1 (mice) [71]. 
CLH = 
fup×CLint, in vivo×Qh
Qh+ fup× CLint, in vivo Rb⁄
 (8)
For compounds which are cleared renally, unbound renal clearance (CLR) was predicted using the 
GFR approach described by Lin [71] and by assuming a rat/human GFR ratio of 4.8 and a 
mouse/human GFR ratio of 6.6 (Mouse GFR = 12 mL/min/kg [74]), corrected for rat fuplasma. 
Permeability rate-limited transport across the BBB was described by Equations (9) and (10). 
Vascular compartment: 
dܥ୴
dt ൌ
ܳ୲
௩ܸ
ൈ ܥୟ୰୲ െ ܳ୲௩ܸ ൈ ܥ୴ െ
CL୮ୟୱୱ୧୴ୣ,୐୅
௩ܸ
ൈ ݂u୮ ൈ ܥ୴ ൅
CL୮ୟୱୱ୧୴ୣ,୅୐
௩ܸ
ൈ ݂uୠ ൈ ܥୣ୴ ൅ CLୟୡ୲୧୴ୣ௩ܸ ൈ ݂uୠ ൈ ܥୣ୴ (9)
Extra-vascular compartment: 
dܥୣ୴
dt ൌ
CL୮ୟୱୱ୧୴ୣ,୐୅
ܸୣ ୴ ൈ ݂u୮ ൈ ܥ୴ െ
CL୮ୟୱୱ୧୴ୣ,୅୐
ܸୣ ୴ ൈ ݂uୠ ൈ ܥୣ୴ െ
CLୟୡ୲୧୴ୣ
ܸୣ ୴ ൈ ݂uୠ ൈ ܥୣ୴ െ
ܳୠ୤
ܸୣ ୴ ൈ ݂uୠ ൈ ܥୣ୴ (10)
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where Qt is tissue perfusion rate, Vev is extra-vascular volume, Vv is the vascular volume,  
CLpassive is the passive clearance across the BBB (subscript denotes either luminal-to-abluminal or  
abluminal-to-luminal flux), fup is free drug fraction in plasma and fub is free drug fraction in brain.  
Permeability rate-limited transport across the BCSFB was described by Equations (11) and (12). 
CP compartment: 
dܥୡ୮
dt ൌ
ܳ୲
ୡܸ୮
ൈ ܥୟ୰୲ െ ܳ୲ୡܸ୮ ൈ ܥୡ୮ െ
CL୮ୟୱୱ୧୴ୣ,୆୅
ୡܸ୮
ൈ ݂u୮ ൈ ܥୡ୮ ൅
CL୮ୟୱୱ୧୴ୣ,୅୆
ୡܸ୮
ൈ ݂uୌ୊ ൈ ܥୌ୊ െ CLୟୡ୲୧୴ୣୡܸ୮ ൈ ݂u୮ ൈ ܥୡ୮ (11)
CSF compartment: 
dܥୌ୊
dt ൌ
ܳୠ୤
େܸୗ୊
ൈ ݂uୠ୰ୟ୧୬ ൈ ܥୣ୴ െ ܳ୲େܸୗ୊ ൈ ܥୌ୊ ൅
CL୮ୟୱୱ୧୴ୣ,୆୅
େܸୗ୊
ൈ ݂u୮ ൈ ܥୡ୮ െ CL୮ୟୱୱ୧୴ୣ,୅୆େܸୗ୊ ൈ ݂uୌ୊ ൈ ܥୌ୊ ൅
CLୟୡ୲୧୴ୣ
େܸୗ୊
ൈ ݂u୮ ൈ ܥୡ୮ (12)
where Qt is the perfusion rate, Vcp is choroid plexus cellular volume, VCSF is the CSF volume, CLpassive 
is the passive clearance across the BCSFB (subscript denotes either basolaterial-to-apical (BA)  
or apical-to-basolaterial (AB) flux), fub is free drug fraction in brain, fup is free drug  
fraction in plasma, fuCSF is free drug fraction in CSF and Cev is the concentration in the brain  
extravascular compartment. 
2.1.2. Extrapolation of Passive Transport 
Where apparent permeability (Papp) was reported in the absence and presence of transporter 
inhibitor, passive transport was assumed to be represented by the extent of inhibition. Where apparent 
permeability was reported in wild type and knock-out animals, passive transport was assumed to be the 
difference in apparent permeability. Passive bi-directional transport across the brain capillary was 
assumed to be represented by the apical-to-basolateral flux (Papp,AB) and basolateral-to-apical flux 
(Papp,BA) in the non-transfected LLC-PK1 cell line (by correcting for the insert surface area (0.33 cm2) 
and expressed as cm/h), and extrapolated to in vivo CLpassive for the luminal-to-abluminal  
(blood-to-brain) and abluminal-to-luminal (brain-to-blood) directions. Passive transport was effectively 
extrapolated to an in vivo passive clearance term based on correction for in vivo brain vascular 
endothelial surface area (SA), 150 cm2 g brain−1 for rats [75] and 240 cm2 g brain−1 for mice [44] and 
brain weight (rat: 0.57% of body weight; mouse: 1.6% of body weight [58]) yielding CLpassive,LA 
(Equation (13)) or CLpassive,AL (Equation (14)). 
CL୮ୟୱୱ୧୴ୣ,୐୅ ൌ ܲapp୅୆ ൈ SA ൈ Brain weight (13)
CL୮ୟୱୱ୧୴ୣ,୅୐ ൌ ܲapp୆୅ ൈ SA ൈ Brain weight (14)
No studies have directly correlated drug permeability, in vitro or in vivo, at the BCSFB and the 
BBB. However, the in vivo permeability-surface area product (PS) of quinolone antibiotics at the 
choroid plexus [76,77] has been modeled in rats, and whilst based on pharmacokinetic modeling 
approaches, yielded similar in vivo permeabilities at the BBB (PSBBB) and BCSFB (PSCSF), when 
corrected for tissue weight. Furthermore the paracellular permeability of sucrose in monolayers of 
primary rat brain endothelial cells (average of 5 studies: 2–11 × 10−6 cm/s [78–82], is similar to that 
reported in monolayers of primary rat choroid plexus cells (7 × 10−6 cm/s [83]). 
Due to the absence of either in vitro or in vivo choroidal epithelial permeability data for many 
compounds, passive flux across the BCSFB was extrapolated based on correcting for in vivo choroid 
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plexus surface area (75 cm2 in rats [27]) to yield an in vivo permeability clearance at the BCSFB 
(CLpassive, BCSFB) (Equation (15)): 
CL୮ୟୱୱ୧୴ୣ ൌ ୟܲ୮୮ ൈ SA (15)
Bi-directional flux (CLpassive, apical-to-basolaterial and CLpassive, basolaterial-to-apical) and active efflux at the 
BCSFB was parameterised using a similar approach to that detailed for the BBB. 
When using in vivo reported CLpassive to describe passive permeability at the BBB, CLpassive at the 
BCSFB was scaled based on the BCSFB:BBB surface area. 
2.1.3. Extrapolation of Active Transport  
Effective extrapolation of in vitro determined active transport data requires knowledge of cellular 
transporter expression within the in vitro system and within the target tissue to account for variations 
in transporter expression. To address this, Ball et al. [43] reported an approach that utilised either  
a relative activity factor (RAF) or a physiological scaling factor to relate activity/expression of 
transporters within in vitro systems to an in vivo metric. Furthermore, Hoffmeyer et al. [84] suggested 
that the transport activity of P-glycoprotein in human is dependent on the level of protein expression. 
Similarly, Shirasaka et al. [85] and Tachibana et al. [86] also demonstrated that P-glycoprotein 
transport activity in vivo was proportional to its protein expression levels in vitro. Given these findings 
we have assumed mdr1a activity is directly related to mdr1a protein expression level and the in vitro 
intrinsic transport activity of mdr1a (transport rate per mdr1a protein) is identical to that in vivo in rats. 
The availability of P-glycoprotein and BCRP efflux kinetics terms is limited for a vast number of 
compounds in the literature and hinders widespread utilisation of PBPK modeling to assess the brain 
distribution of drugs. In lieu of widespread and robust Michaelis–Menten kinetics parameters for 
transporter substrates, the active efflux component of drug transport was described by a corrected 
efflux ratio (ER) [55,87] (Equation (16)) derived from the ratio of the efflux ratio in mdr1- or  
BCRP-transfected cells and vector-transfected control cells.  
ERcorrected = 
ERfunctional
ERnon-functional
 (16)
To correct for the difference in protein abundance between in vitro cell lines and brain capillaries, 
an abundance-scaling factor (ASF) was incorporated to represent the ratio of in vivo-to-in vitro 
capillary abundance of transporter protein in cell lines (see Section 2.1.5) and either mice  
(P-glycoprotein; 14.1 fmol/μg protein or BCRP; 4.41 fmol/μg protein [56]) or rats (P-glycoprotein; 
19.1 fmol/μg protein or BCRP; 4.95 fmol/μg protein [57]). For BCRP, in vitro abundance data were 
not available in the MDCK-II-BCRP cell line and therefore ASF was set as equal to 1. Subsequently 
active clearance was incorporated into the model as the product of the corrected in vivo efflux ratio and 
luminal-to-abluminal passive clearance (Equation (17)). 
CLactive = ERcorrected × CLpassive,LA × ASF (17)
Active efflux at the BCSFB was modelled using a similar approach, with directionality of efflux 
transport being from the systemic circulation into the CSF. The proposed model incorporates active 
efflux for two widely investigated drug efflux transporters, P-glycoprotein and BCRP. Alternative 
Pharmaceutics 2014, 6 106 
 
transporter proteins with similar transport directionality could be paramatised within the model using 
in vitro passive and active permeability data for a specific transporter protein along with the protein 
abundance of the transporter(s). 
2.1.4. Model Validation: Prediction of Temporal Brain and Plasma Concentrations in Rats 
To validate the PBPK model the plasma and brain concentrations of the antibiotic norfloxacin were 
modeled and compared to in vivo measurements in rats. Norfloxacin plasma pharmacokinetics in rats, 
following an intravenous (IV) bolus of 150 mg kg−1, has been described by a 2-compartment  
model [88]. For modeling purposes, the unbound fraction of norfloxacin in brain was assumed to be 
equal to 1. This approach can be rationalised since the unbound brain volume of distribution  
(Vu,brain) [89] for norfloxacin (0.98 ± 0.59 mL g brain−1), is similar to the brain water volume  
(0.8 mL g brain−1) [90] suggesting limited brain binding. Predicted norfloxacin brain ISF- and plasma 
concentration-time profiles were compared with in vivo norfloxacin brain ISF (determined using 
microdialysis) and plasma concentration-time profiles from 10 rats (pharmacokinetic data provided by 
Chenel et al. [88]). 
2.1.5. Prediction of Kpuu,brain and CSFu:Plasmau in Rat 
The rat CNS hybrid PBPK model was used to predict Kpuu,brain and CSFu:Plasmau. Permeation 
across the BBB and BCSFB was incorporated into the model using in vitro permeability determined in 
the L-mdr1a cell line, as reported by Uchida et al. [55] and detailed in Section 2.1.3. All compounds 
were simulated as intravenous bolus doses. Kpuu,brain and CSFu:Plasmau were predicted for a dataset of 
25 compounds where in vitro permeability, fuplasma, fubrain, fuCSF, Kpuu,brain and CSFu:Plasmau had 
previously been reported in rats [53] (see Supplementary Information). 
2.2. Prediction of Kpuu,brain for Actively Effluxed Compounds in Mice 
In order to assess the utility of in vitro-derived cell culture permeability data to predict CNS drug 
disposition for actively effluxed compounds in mice, a whole body CNS PBPK model was 
parameterised with physiological tissue volumes and perfusion rates obtained from literature [91], with 
any absent data assumed to be equivalent to rats [59,60]. Permeation across the BBB and BCSFB was 
incorporated into the model using in vitro permeability determined in the L-mdr1a cell line, as reported 
by Uchida et al. [55] and the brain disposition of 11 P-glycoprotein substrates was modeled and 
predictions compared to reported Kpuu,brain in mice [55]. All compounds were simulated as intravenous 
bolus doses. 
2.3. Sensitivity Analysis 
To further explore the factors that influence the disposition of drugs into the brain biophase, a series 
of additional simulations were conducted exploring the impact of variation in CLpassive  
(luminal-to-abluminal and abluminal-to-luminal were assumed equal), ER, fuplasma and fubrain on 
Kpuu,brain and CSFu:Plasmau utilising input parameters based on a model compound selected from the 
Kpuu,brain and CSFu:Plasmau predictions. 
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2.4. Assessment of Prediction Accuracy 
The predictability of individual compounds was assessed using a fold-error (FE) approach where: 
Predicted > Observed: 
FE=
predicted
observed
 (18)
Observed > Predicted: 
FE=
observed
predicted
 (19)
Prediction accuracy was assessed by the average fold error (afe) approach (geometric mean error) 
(Equation (20)): 
݂ܽ݁ ൌ 10ቂభ౤∑ ୪୭୥౦౨౛ౚ౟ౙ౪౛ౚ౥ౘ౩౛౨౬౛ౚቃ (20)
Precision of prediction was assessed using root mean squared error (rmse) (Equation (21)) where  
n refers to the number of observations. 
ݎ݉ݏ݁ ൌ ඨ1݊෍ሺprediction െ observedሻଶ (21)
The percentage of compounds within a 3-fold, 4-fold, 5-fold and >5-fold error was derived from 
predicted and observed values. 
3. Results and Discussion 
The availability of in vivo permeability measurements for candidate compounds undergoing  
pre-clinical assessment often remains a limiting factor for efficient and effective use of 
pharmacokinetic models attempting to model CNS drug disposition. Consequently, in vitro 
permeability data for passively and actively transported compounds are often used to extrapolate to  
in vivo permeability. Polli et al. [92] demonstrated a linear relationship between brain penetration 
(Kin) in rat in situ brain perfusion studies and apparent permeability in MDCK type-1 cells with a 
correlation coefficient of 0.86. A similar trend was reported between brain uptake index (BUI) and 
permeability across bovine brain endothelial cell cultures, with a correlation coefficient of 0.89 [50].  
In more recent studies Uchida et al. [54] and Kodaira et al. [53] have demonstrated the utility of 
murine-mdr1a-expressing LLC-PK1 cells (L-mdr1a) to reconstruct Kpuu,brain and CSFu:Plasmau for a 
handful of P-glycoprotein substrates. 
Our primary goal was to build upon existing approaches aimed at mechanistically predicting CNS 
drug disposition and examine the potential application of drug permeability data derived from L-mdr1a 
cells to predict Kpuu,brain in mice and both Kpuu,brain and CSFu:Plasmau in rats. Development of a PBPK 
model capable of predicting CNS drug disposition by extrapolation of in vitro-derived data may prove 
a valuable resource for rapid pre-clinical screening of candidate compounds during development. 
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3.1. Validation of the PBPK Model 
To validate the PBPK model structure and the ability to predict both plasma and brain ISF temporal 
concentrations, we selected norfloxacin as a model compound and utilised published rat norfloxacin 
plasma data and brain pharmacokinetic data obtained by microdialysis [88]. 
Norfloxacin plasma (Figure 2) and brain (Figure 3) temporal concentration profiles were both 
predicted to be within the ranges observed in vivo. Simulation of brain ISF norfloxacin concentration-time 
profile using literature derived CLpassive (value obtained from fitting to in vivo data) [76,77] in the 
absence of a P-glycoprotein/BCRP-type active efflux component yielded predictions in which the 
absorption and elimination phases were outside the range observed in vivo (Figure 3). Subsequent 
simulations using a CLpassive 2-fold higher than the initial fitted value (Table 2) and  
P-glycoprotein/BCRP-type active efflux processes (efflux ratio of 3) resulted in absorption and 
elimination phases within the range reported in 10 rats by Chenel et al. [88] (Figure 3). 
Importantly, incorporation of an active efflux component (P-glycoprotein/BCRP type) within our 
simulations corrected the over-prediction in brain ISF drug concentrations and demonstrated the 
importance of an efflux clearance mechanism in governing norfloxacin CNS drug disposition. These 
findings are consistent with those of Chenel et al. [88] who demonstrated the influence of efflux 
clearance mechanisms on norfloxacin brain pharmacokinetics. The inclusion of a P-glycoprotein/BCRP 
type active efflux component within our norfloxacin simulations is supported by a recent report 
demonstrating norfloxacin to be a BCRP substrate [93]. 
Figure 2. Model predicted norfloxacin plasma concentrations in rats. Small closed circles 
represent literature reported plasma concentrations determined in rats following an  
IV-bolus dose [88]. Large closed circles represent model predicted norfloxacin plasma 
concentrations in rats in the absence of efflux. Large open circles represent model predicted 
norfloxacin plasma concentrations in rats in the presence of efflux (efflux ratio = 3). 
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Figure 3. Model predicted norfloxacin brain concentrations in rats. Crosses represent 
literature reported brain concentration determined in rats following an IV-bolus dose [88]. 
Closed circles represent model predicted norfloxacin brain concentrations in rats in the 
absence of efflux. Open circles represent model predicted norfloxacin brain concentrations 
in rats in the presence of efflux (efflux ratio = 3). 
 
Norfloxacin Kpbrain was predicted to be 0.141, within 2-fold of the observed Kpbrain of 0.091, whilst 
norfloxacin CSF:plasma was predicted to be 0.089, within 2.1-fold of the observed CSF:plasma of 
0.043 (Table 2). Predicted plasma half-life was extremely close to observed half-life whilst brain ISF 
half-life was within 1.5-fold of the observed value (Table 2). 
Table 2. Prediction of norfloxacin plasma, brain and CSF pharmacokinetics. 
Parameter Value Unit 
Predicted Kpbrain 0.141  
Mean observed Kpbrain 0.093 a  
Predicted CSF:Plasma 0.089  
Observed CSF:Plasma 0.043 b  
Predicted t1/2,plasma (ER = 3) 183 (min−1) 
Observed t1/2,plasma c 202 ± 45 (min−1) 
Predicted t1/2,ISF (ER = 3) 231 (min−1) 
Observed t1/2,ISF d 255 ± 97 (min−1) 
Predicted AUCplasma 340 (µM min−1) 
Predicted AUCISF (ER = 0) 329 (µM min−1) 
Predicted AUCISF (ER = 3) 47.9 (µM min−1) 
Predicted AUCCSF (ER = 3) 30.4 (µM min−1) 
Predicted ISF Cmax (ER = 0) 52.4 (µM) 
Predicted ISF Cmax (ER = 3) 16.3 (µM) 
a Mean of three reported values (Kpu,brain: 0.035 ± 0.014 and Kpbrain: 0.044 [77], Kpbrain: 0.097 ± 0.029 [76] and 
0.067 [89]); b Mean of two reported values (CSF:Pu, 0.033 ± 0.006 and CSF:P, 0.042 [77], CSF:Pu, 0.044 ± 0.010 
and CSF:P, 0.056 [94]); c Reported parameter estimate from compartmental analysis [88]; and d Reported 
parameter estimate from non-compartmental analysis [95]. 
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3.2. Prediction of Central Nervous System (CNS) Disposition Using L-mdr1a in Vitro Permeability Data 
Recent studies report positive correlations between drug permeability assessed in the LLC-PK1 
porcine kidney cell line transfected with murine mdr1 (to produce the L-mdr1a cell line) and in vivo 
brain distribution of P-glycoprotein substrates in rats and mice [53]. 
Furthermore, due to the similarity in the abundance of P-glycoprotein in L-mdr1a cells  
(15.2 fmol/μg protein) compared to the abundance in brain capillaries (Mouse: 14.1 fmol/μg protein [56]; 
rat: 19.1 fmol/μg protein [57]), we examined the use of L-mdr1a-derived in vitro permeability data in 
predicting CNS drug disposition. 
In an attempt to examine the validity of the scaling approach to determine permeability clearance at 
the BBB, based on extrapolating in vitro permeability data, we obtained literature reported in situ brain 
permeability-surface area products (PS) for 16 compounds spanning over a 100-fold range of PS. 
With the exception of three compounds (midazolam, diazepam and sertraline), 11 of 13 compounds 
fell within 3-fold and 2 within 4-fold of the reported PS values (see Supplementary Information 
Section 4). Similar trends have been previously reported by Uchida et al. (2011) in LLC-PK1 cells [55], 
Polli et al. (2000) [92] and Summerfield et al. (2007) [96] in cultured kidney epithelial cells, and 
support the extrapolation approach. 
3.2.1. Prediction of Kpuu,brain for 11 Actively Transported Compounds in Mice 
Using L-mdr1a-derived permeability data reported by Uchida et al. [55], the predicted Kpuu,brain for 
over 90% of P-glycoprotein substrates was within 4-fold of observed Kpuu,brain. The predicted Kpuu,brain 
for all compounds was within 5-fold of observed Kpuu,brain (Figure 4A,B), with an overall afe and rmse 
of 0.7 and 0.23 respectively (Table 3). 
Figure 4. Comparison of predicted and reported Kpuu,brain in mice. (A) Solid bold  
mid-line represents the line of unity and solid outer-lines represent 4-fold prediction error;  
and (B) residuals plot. 
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Table 3. Statistics for the model predictions. 
Species Tissue n afe rmse 
% within 
3-fold 
% within 
4-fold 
% within 
5-fold 
% >  
5-fold 
Mouse Brain 11 0.7 0.23 63.6 90.9 100 0 
Rat 
Brain 27 1.19 0.43 63 81.5 88.9 11.1 
CSF 27 0.8 0.32 77.8 81.5 96.3 3.7 
Uchida et al. [55] successfully demonstrated that Kpbrain (and Kpuu,brain) could effectively be 
reconstructed though the integration of in vitro mdr1a transport activity and mdr1a protein expression 
levels in the brain capillaries and in mdr1a-transfected cell monolayers. Our model yielded reasonable 
predictions for passively transported and actively transported P-glycoprotein substrates and 
demonstrated the successful extrapolation of in vitro permeability data to yield an in vivo transfer 
clearance across the brain capillaries. 
The basis of these predictions is quantitative calculation of the temporal drug concentrations in 
plasma and brain compartments. Whilst Uchida et al. [55] initially reconstructed Kpuu,brain, for the  
first time we have shown that, using a well-designed PBPK modeling approach, plasma and brain  
ISF temporal concentrations, and Kpuu,brain can be adequately predicted in mice for a range of  
P-glycoprotein substrates, using a simple set of physiochemical and pre-clinically determined parameters. 
3.2.2. Prediction of Rat Kpuu,brain and CSFu:Plasmau 
In an attempt to assess the utility of L-mdr1a-derived permeability data to predict cross-species 
CNS distribution, we utilised L-mdr1a permeability data from 25 compounds to predict in vivo CNS 
distribution (Kpuu,brain and CSFu:Plasmau) in rat. Our reported model was capable of predicting rat brain 
disposition (Kpuu,brain) for 81.5% of compounds simulated to within 4-fold of the reported Kpuu,brain 
(Table 3 and Figure 5). The predicted Kpuu,brain of quinidine was within 6.8-fold of observed Kpuu,brain, 
whilst that of loperamide within 7.4-fold. The overall afe and rmse were 1.19 and 0.43 respectively 
(Table 3). 
Predicted Kpuu,brain, for compounds with observed Kpuu,brain less than 0.01 and greater than 1 
deviated further from the line of unity (Figure 5A and local regression (LOESS) plot in Supplementary 
Information Section 5) but were nevertheless predicted within 4-fold of the reported Kpuu,brain. 
For flavopirodol and perfloxacin, the use of either MDCKII or LLC-PK1-derived cell permeability 
data did not significantly alter model predictions.  
Kpbrain for P-glycoprotein substrates ranges from 1 to 50 [97]. The Kpuu,brain of quindine and 
loperamide, typical P-glycoprotein substrates, were 7.4-fold over-predicted in our model. Recent 
reports have identified a 39.4-fold [55] to 44-fold [53] increase in Kpbrain when comparing wild-type to 
knock-out mice for quinidine and 23.3-fold [55] for loperamide. For these highly effluxed compounds, 
the use of in vitro permeability data may not truly reflect the extent of in vivo efflux and therefore the 
use of knock-out-to-wild-type Kpbrain (or Kpuu,brain) could also be used as a surrogate metric for efflux. 
Such an approach improved model predictions of both loperamide (Kpuu,brain = 0.025) and quinidine 
(Kpuu,brain = 0.071) to within a 3-fold prediction window (see Supplementary Information Section 6). 
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Figure 5. Comparison of predicted and reported Kpuu,brain in rat. (A) Solid bold mid-line 
represents the line of unity and solid outer-lines represent 4-fold prediction error;  
and (B) residuals plot. 
 
The rat CNS whole-body PBPK model was successful in predicting CSFu:Plasmau for 81.5% of 
compounds to within 4-fold of observed CSFu:Plasmau (Table 3 and Figure 6A,B), with CSFu:Plasmau 
of benzylpenicillin 5.8-fold over predicted. The overall afe and rmse were 0.8 and 0.32  
respectively (Table 3). 
Figure 6. Comparison of predicted and reported CSFu:Plasmau in rat. (A) Solid bold  
mid-line represents the line of unity and solid outer-lines represent 4-fold prediction error;  
and (B) residuals plot. 
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3.3. Model Sensitivity Analysis 
Several parameters, particularly passive clearance, active efflux, fubrain and fuplasma, have the 
potential to significantly impact CNS drug distribution by influencing drug clearance across the BBB 
and BCSFB. To further explore the relationship between drug clearance across the BBB and BCSFB 
and the extent of protein/tissue binding, risperidone was selected as a model candidate compound and 
the impact of variation in passive clearance, active efflux, fubrain and fuplasma on Kpuu,brain and 
CSFu:Plasmau was assessed. 
3.3.1. Passive Clearance 
3.3.1.1. Impact of Variation in fuplasma and fubrain on Kpuu,brain and CSFu:Plasmau 
Irrespective of whether the passive clearance (CLpassive) (i.e., passive permeability) of risperidone at 
the BBB and BCSFB was low (CLpassive 0.34 mL/h) or high (64 mL/h), increasing fuplasma (from 0.001 
to 1) resulted in a substantial increase in Kpuu,brain across the range of fubrain (0.001 to 1) simulated 
(Figure 7A: transparent mesh indicates high permeability condition; coloured profile indicates low 
permeability condition). 
Under conditions of both low and high CLpassive, an increase in fubrain (from 0.001 to 1) was 
associated with a decrease in brain partitioning (Kpuu,brain) of risperidone. This decrease was observed 
across the range of fuplasma (0.001 to 1) simulated (Figure 7A: transparent mesh indicates high 
permeability condition; coloured profile indicates low permeability condition). 
Overall, Kpuu,brain at high CLpassive was greater than Kpuu,brain at low CLpassive when fubrain < 0.1. 
Brain penetration is therefore influenced by the extent of plasma protein binding (fuplasma) and the 
extent of drug binding within the brain (fubrain). Whilst these observations are relatively intuitive, the 
importance of both fuplasma (and hence unbound drug concentration in plasma) and drug permeability 
across CNS barriers in influencing CNS drug disposition is clearly demonstrated for drugs that exhibit 
high non-specific binding to brain tissue (fubrain). For drugs that are highly bound to brain, fuplasma 
drives entry of drug into the brain. Such drugs are retained within the bulk of the brain  
(bound-unbound cycling) creating a sink effect, and increasing BBB CLpassive would enhance this sink 
effect further increasing Kpuu,brain [98–100]. 
The disposition of drug into the CSF was demonstrated to be sensitive to fuplasma, with increased 
CSFu:Plasmau associated with increasing fuplasma. This finding was apparent for both low and high 
CLpassive conditions (Figure 7B: transparent mesh indicates high permeability; coloured profile 
indicates low CLpassive conditions). However, simulations were insensitive to any change in fubrain 
(0.001–1) (Figure 7B). These simulations demonstrated no apparent relationship between the extent of 
fubrain and CSFu:Plasmau, suggesting fubrain alone does not significantly influence the unbound 
concentration of drug within the CSF. These findings support the notion that the extent of free drug in 
plasma is an important factor influencing drug penetration across the BCSFB into the CSF. 
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Figure 7. Sensitively analysis of the whole-body physiologically based pharmacokinetic 
(PBPK) model. The impact of variations in fubrain, fuplasma, CLpassive and efflux ratio on 
Kpuu,brain and CSFu:Plasmau. 
 
3.3.1.2. Impact of Variation in fubrain and CLpassive on Kpuu,brain 
Irrespective of the extent of plasma protein binding (fuplasma 0.01 (low) or 1 (high)), Kpuu,brain was 
insensitive to changes in CLpassive at higher fubrain (fubrain > 0.1) (Figure 7C: transparent mesh indicates 
high fuplasma; coloured profile indicates low high fuplasma). The sensitivity of Kpuu,brain to changes in 
CLpassive increased as fubrain decreased (<0.1) (Figure 7C). 
As already established, fuplasma determines the unbound plasma drug concentration available to 
penetrate the BBB and BCSBF, where higher fuplasma results in an increase in the unbound drug 
concentration available to cross the BBB and BCSFB. Equally, drug binding in brain provides a 
driving force for retention of drug within the brain mass, which is evident by the increasing Kpuu,brain as 
fubrain decreases (irrespective of changes in CLpassive). However the important role fubrain plays in 
determining Kpuu,brain for highly brain-bound drugs (fubrain < 0.1) is particularly evident for lower 
permeability compounds (CLpassive < 1); Kpuu,brain appeared not to change significantly when fubrain  
was between 0.001 and 0.1. However Kpuu,brain was reduced when fubrain was between 0.1 and 1  
(these findings were observed with both high fuplasma and low high fuplasma conditions). 
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3.3.2. Active Clearance 
3.3.2.1. Impact of Variation in fubrain and Active Efflux on Kpuu,brain 
Irrespective of the extent of plasma protein binding (fuplasma: 0.01 (low) or 1 (high)), Kpuu,brain was 
influenced by variations in both fubrain over the range studied (fubrain 0.001–1) and efflux ratio (2–100) 
(Figure 7D: transparent mesh indicates high fuplasma; coloured profile indicates low fuplasma). Kpuu,brain 
increased as fubrain decreased from 1 to 0.001, with extensive brain accumulation (Kpuu,brain greater than 1) 
when fuplasma was high (fuplasma = 1) (Figure 7D). 
The increase in Kpuu,brain as fubrain decreases can be rationalised by considering that Kpuu,brain is 
largely driven by a combination of membrane permeability (passive and active) and drug free fraction 
in plasma and brain. Where permeability is low (<0.5 mL/h) the impact of variation in fubrain on 
Kpuu,brain is limited (Figure 7C). When passive permeability increases (CLpassive > 0.5 mL/h), and with 
increasing active efflux at the BBB (Figure 7D), the extent of dug passive permeability may augment 
Kpuu,brain and counter the impact a reduction in fubrain would have on Kpuu,brain. 
3.3.2.2. Impact of Variation in CLpassive and Efflux Ratio on Kpuu,brain 
The extent of non-specific binding of drug in brain (fubrain) had a significant effect on the sensitivity 
of Kpuu,brain to CLpassive and to active efflux (Figure 8). When drug was highly bound in brain (Figure 8A: 
fubrain = 0.01 and fuplasma = 1), increasing the extent of drug efflux (efflux ratio 2–50) resulted in a 
progressive decrease in Kpuu,brain, which was more apparent at higher CLpassive (>10 mL/h). 
Interestingly, at lower CLpassive (<1 mL/h), increasing the extent of active efflux had minimal effects 
on Kpuu,brain compared to higher CLpassive (>1 mL/h). This effect was diminished when fubrain was high 
(Figure 8B: fubrain = 1 and fuplasma = 1), since Kpuu,brain was not sensitive to changes in CLpassive over a 
range of efflux ratios (2–50). 
Figure 8. Sensitively analysis of the whole-body PBPK model. The impact of variations in 
fubrain (A) low fubrain and (B) high fubrain, CLpassive and efflux ratio on Kpuu,brain (see text  
for details). 
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Fubrain governs the unbound drug concentration in brain and, in conjunction with the clearance of 
drug across the BBB, helps to regulate the rate and extent of CNS drug accumulation. With extensive 
non-specific drug binding in brain tissue (Figure 8A), Kpuu,brain was higher than when fubrain is not a 
limiting factor (Figure 8B). In the absence of an efflux effect the sensitivity of Kpuu,brain to fubrain, 
particularly at low CLpassive (Figure 8A), may reflect enhancement of the sink effect as drug is readily 
able to cross the BBB and accumulate within the brain mass with a diminished abluminal-to-luminal 
clearance. As active efflux increases, this effect is diminished as efflux provides an additional driving 
force to rebalance the partition of drug between intravascular spaces and brain biophase. 
4. Conclusions 
With development of therapeutic drugs targeted to the CNS lagging behind development of drugs 
for other therapeutic areas there is an urgent requirement to better predict CNS drug disposition. The 
application of brain microdialysis and PET imaging techniques will provide a true quantitative 
understanding of the temporal (regional) brain concentrations, but the techniques and equipment 
needed for their applications in understanding CNS drug disposition is often a limiting factor to their 
widespread use. 
To address this issue, we have developed a mechanistic, whole-body physiologically-based 
pharmacokinetic model incorporating both brain biophase (brain ISF) and cerebrospinal fluid 
compartments, which provided reasonable estimates of brain-to-plasma and CSF-to-plasma ratios 
using routinely determined experimental parameters (e.g., in vitro permeability, efflux ratio, fuplasma or 
fublood and fubrain). This model not only allows the simultaneous prediction of brain-to-plasma and  
CSF-to-plasma ratios and examination of the impact of drug permeability and blood flow on CNS drug 
disposition, but allows a quantitative prediction of unbound drug concentration within the CNS. 
Despite the lack of availability of in vitro permeability data from representative in vitro choroid 
plexus cell models (such as the immortalised Z310 rat cell line [101]), the model adequately predicted 
CSF-to-plasma ratios for over 90% of the compounds simulated. The lack of predictive models 
currently capable of quantifying both brain biophase and CSF drug disposition significantly hinders 
the assessment of drug disposition within the CNS. Current methods utilising CSF drug kinetics as 
surrogates for brain drug kinetics remain controversial [95,102], with many studies disagreeing with 
the use of CSF as a surrogate for brain [103–105]. The physiological differences between the BCSFB 
and the BBB, advocate the viewpoint that CSF and BCSFB are distinct entities when compared to the 
BBB. In particular, since CSF drug concentrations do not accurately reflect brain drug concentrations 
for many actively transported compounds, it is essential that the brain and CSF be considered as 
separate entities within mechanistic models. 
Clearly, in the context of the interactions of drug substrates with transporter proteins, the benefit of 
the proposed PBPK model would be to effectively incorporate the impact of temporal concentrations 
on transporter activity and the impact this would have on CNS pharmacokinetics. 
The proposed model is capable of predicting temporal CNS drug concentrations, however due to 
the lack of routinely available transporter-specific Michaelis–Menten terms for drug substrates, the 
proposed approach of examining overall CNS disposition (Kpuu,brain and CSFu:Plasmau) is a valid one. 
In addition, the complexity of modeling the kinetics of drug-transporter protein interaction, at a 
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cellular level, is now recognised and could potentially be examined further within the proposed model 
if BBB and BCSFB cellular compartments were expanded towards a semi-systems biology based 
model [106]. It is prudent to note however, that such approaches would benefit from the use of 
microdialysis or PET imaging in combination with more elaborate semi-systems biology models, to 
aid in the development and validation of models. 
The present study reports, for the first time, a PBPK CNS model that predicts Kpuu,brain and 
CSF:Plasma (bound and unbound) for compounds possessing diverse pharmacokinetic characteristics. 
Additionally, this study illustrates the potential use of in vitro L-mdr1a-derived permeability data to 
predict rat CNS drug disposition within an acceptable tolerance. 
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Supplementary Information 
S1. Model Validation: Prediction of Norfloxacin Temporal Brain and Plasma Concentrations in Rats 
Table S1. Model input parameters. 
Parameter Value Units 
Permeability Clearance a   
CLpassive 0.21 mL/h 
Efflux b   
Efflux ratio 3  
Unbound fraction   
fuplasma c 0.78  
fubrain d 1  
fuCSF e 1  
Physicochemcial   
LogP f −1.03  
pKa g 6.4 and 8.7 (Zwitterion)
Total plasma clearance   
CL h 15.5 mL/min/kg 
a Mean of reported values from Ooie et al. [76]; b Reported as apical-to-basolateral/basolateral-to-apical flux [107];  
c Taken from Ooie et al. [77]; d Estimated from Vu,brain [89]; e Total CSF concentrations were simulated as 
only CSF:Plasmau have been reported in literature; f Taken from Hansch et al. [108]; g Calculated using 
ChemAxon; and h Total plasma clearance [88] is split between hepatic (85%) and renal (15%) clearance [109]. 
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S2. Mouse PBPK Model Compound Specific Parameters 
Table S2. Mouse PBPK model parameters. 
Compounds 
In vitro permeability a Active efflux Permeability clearance 
Papp (L-mdr1a) Papp (LLC-PK1)  
Efflux ratio 
 
mL/h 10−6 cm/s 10−6 cm/s 
A to B B to A A to B B to A ERfunctional ERnon-functional ERcorrected CLpassiveLA CLpassiveAL CLactive
Quininde 3.16 146 57.2 80.5 46.2 1.4 30.2 14.8 20.9 447.8 
Loperamide 5.49 271 49.7 98 49.4 2 23 12.9 25.4 296.7 
Digoxin 1.13 31.9 11.8 18.8 28.2 1.6 16.3 3.1 4.9 49.9 
Risperdone 23.3 150 96.3 58.7 6.4 0.6 9.7 25 15.2 242.5 
Indindavir 3.33 45.3 14.4 20.5 13.6 1.4 8.8 3.7 5.3 32.8 
Dexamethasone 6.91 102 29.5 36.5 14.8 1.2 11 7.6 9.5 83.9 
Vinblastine 2.83 56.1 24.2 38.7 19.8 1.6 11.4 6.3 10 71.5 
Paclitaxcel 2.7 53.8 20.5 33.2 19.9 1.6 11.3 5.3 8.6 60.1 
Verapamiol 11.9 84 73.5 39 7.1 0.5 12.2 19.1 10.1 233.2 
Loratidine 32 80.2 23.1 33.1 2.5 1.4 1.6 6 8.6 9.6 
Diazepam 57.3 67.2 31.8 43.5 1.2 1.4 0.8 8.2 11.3 6.5 
a Taken from Uchida et al. [55]. 
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Table S3. Mouse PBPK metabolic and renal clearance. 
Compounds 
Metabolic clearance  Renal clearance 
Human a Mouse b Human  Mouse 
CLplasma or CLint,u CLint, in vivo CLR 
mL/min/mg protein or mL/min/kg mL/min/kg mL/min/kg 
Quininde 4.02 11.02 0.8 5.28 
Loperamide 0.1775 183.56 na na 
Digoxin 0.07  0.08 2.06 c 13.596 
Risperdone 5.4  10.76 12.8 d 84.48 
Indindavir 14.7  308.30 na na 
Dexamethasone 3.91  6.31 na na 
Vinblastine 15.4 e 221.51 na na 
Paclitaxcel na 0.54 f na na 
Verapamiol 13.3 119.58 na na 
Loratidine na na na na 
Diazepam 0.51 1.88 na na 
a unless otherwise indicated, human clearance values were obtained from Hallifax et al. [110]; b unless 
otherwise indicated, mouse clearance was determined from human clearance (via calculation of human  
in vivo intrinsic hepatic clearance) and allometrically scaled (Human = 70 kg, Mouse = 0.020 kg), see Section 
2.1.1 for further details; c taken from Hedman et al. (1990) [111]; d taken from Thyssen et al. [112]; e taken 
from Rataom et al. [113]; f taken from Eiseman et al. [114]; na: not available. 
S3. Mouse Brain PBPK Model Predictions 
Table S4. Mouse PBPK model predictions. 
Compounds 
Predicted Observed a Fold error 
Kpuu,brain Kpuu,brain  
Quinidine 0.034 0.058 1.7 
Loperamide 0.031 0.016 1.9 
Digoxin 0.021 0.005 4.2 
Risperidone 0.315 0.212 1.4 
Indinavir 0.036 0.119 3.3 
Dexamethasone 0.031 0.093 3 
Vinblastine 0.041 0.025 1.6 
Paclitaxel 0.054 0.116 2.1 
Verapamil 0.025 0.100 4 
Loratidine 0.236 0.740 3.1 
Diazepam 0.588 1.160 1.9 
a Taken from Uchida et al. [55]. 
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S4. Rat CNS PBPK Model  
Table S5. Permeability data. 
Compounds Transporter
Transporter expressing cells a Parental cells Active efflux b 
Papp (μL/h/well) Papp (μL/h/well) Efflux ratio 
A to B B to A A to B B to A ERfunctional ERnon-functional ERcorrected 
Antipyrine  28.7 25.6 31.2 29.6    
Benzypenicillin  7.5 4.7 5.2 3.7    
Buspirone  38.6 38.4 40.7 39.9    
Caffeine  29.7 35.4 32.1 34.5    
Carbamazepine  40.6 45.2 41 46.5    
Cephalexin  4.8 3.7 4 3.7    
Citalopram  25.9 39.2 32 35.5    
Cimetidine BCRP 1.8 7.2 1.2 2.4 4.0 2.0 1.8 
Daidzen BCRP 16.9 36.4 20.5 24.1 2.2 1.2 1.7 
Dantrolene BCRP 19.9 41.9 31.1 36.1 2.1 1.2 1.7 
Diazepam  46.5 42.2 44.4 43.7    
Flavopiridol P-gp 9.6 67.3 26.6 39.6 7.0 1.5 4.3 
Flavopiridol BCRP 42.9 64 54.9 53.6 1.5 1.0 1.4 
Fleroxacin BCRP 5.6 9.9 5.6 6.8 1.8 1.2 1.3 
Genistein BCRP 13.8 32.4 20.7 23.1 2.3 1.1 1.9 
Loperamide P-gp 12.9 54.7 22.1 15 4.2 0.7 5.7 
Midalzolam  38.1 44.5 41.4 42.2    
Pefloxacin P-gp 5.1 12.3 5.4 8.5 2.4 1.6 1.4 
Pefloxacin BCRP 10.8 17.4 9 9.2 1.6 1.0 1.5 
Phenytoin  29.6 37.1 31 37.7    
Quinidine P-gp 6.6 42.2 22.3 22.9 6.4 1.0 5.7 
Risperidone P-gp 21.3 63 41.8 45.9 3.0 1.1 2.5 
Sertraline  2.8 2.4 2.7 1.9    
Sulpiride  2 2.7 1.9 2.4    
Thiopental  39.6 37.7 37.1 36.4    
Verapamil P-gp 15.4 49 24.9 23.4 3.2 0.9 3.1 
Zolpidem  40.3 45.8 42.4 41.6    
a Compounds known to be subjected to active efflux as a result of a transporter protein are indicated by either BCRP (breast cancer resistance protein or P-gp  
(P-glycoprotein); and b calculated only for compounds reported to be subjected to active efflux. 
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Table S6. Model predicted versus literature reported in situ permeabilities. 
Compounds Transporter
Permeability clearance In situ permeability b 
mL/h mL/h CLpassiveLA a CLpassiveAL CLactive 
Antipyrine 25.5 24.2 66 ± 2.5 [115–117] 
Benzypenicillin 4.3 3 0.97 [118] 
Buspirone 33.3 32.6 
Caffeine 26.3 28.2 95 ± 33.7 [100,115,116,119] 
Carbamazepine 10.6 33.5 116 [96] 
Cephalexin 3.3 3 
Citalopram 26.2 29 67.3 [96] 
Cimetidine BCRP 2.9 16.5 5.2 0.58 [120] 
Daidzen BCRP 13.5 (7) 32 23 21.6 (WT), 30 (−/−) [121] 
Dantrolene BCRP 18.4 (8.6) 31.6 31.3 16.7 (WT), 35 (−/−) [121] 
Diazepam 36.3 35.8 351 ± 254 [96,100,122] 
Flavopiridol P-gp 21.8 32.4 181.1 
Flavopiridol BCRP 44.9 43.9 62.9 
Fleroxacin BCRP 4.1 5 5.3 
Genistein BCRP 14.6 27.1 27.7 
Loperamide P-gp 18.1 (8) 12.3 130 2 (WT), 26 (−/−) [123] 
Midalzolam 33.9 34.5 459 [96] 
Pefloxacin P-gp 4.4 7 7.8 
Pefloxacin BCRP 7.4 7.5 11.1 
Phenytoin 25.4 30.8 36.7 ± 21 [96,115,124] 
Quinidine P-gp 18.2 18.7 130.7 7.45 ± 6.35 [116,120,125] 
Risperidone P-gp 34.2 37.6 107.7 101.7 [96] 
Sertraline 2.2 1.6 129 [96] 
Sulpiride 1.6 2 
Thiopental 30.4 29.8 
Verapamil P-gp 20.4 (10.1) 19.1 79.7 6 ± 0.78 (WT) 46.3 ± 8.42 (−/−) [124,126]
Zolpidem 34.7 34 
a Permeabilities in italics represent in vivo passive influx in mice and are used in conjunction with the equivalent in situ brain permeability (italics) for correlation 
purposes; and b values in italics represent in situ brain permeabilities in mice used for correlation purposes.  
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Figure S1. Correlations and confidence interval plots of in situ brain perfusion and 
predictions of CLpassive. 
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Table S7. Physicochemical parameters used to calculate partition coefficients. 
Compounds 
Physicochemical parameters a 
pKa LogP 
Antipyrine 1.4 0.38 b 
Benzypenicillin 3.55 c 2.74 d 
Buspirone 7.62 1.95 e 
Caffeine 14 0.92 f 
Carbamazepine 15.96 2.1 
Cephalexin 3.45 g 0.65 
Citalopram 9.78 3.5 
Cimetidine 6.8 h 0.26 
Daidzen 8.69 0.71 
Dantrolene 7.5 1.65 
Diazepam 3.4 d 2.82 i 
Flavopiridol 5.68 2.8 
Fleroxacin 7.15 1.84 
Genistein 6.35 3.04 
Loperamide 8.6 5.5 
Midalzolam 6.2 3.89 
Pefloxacin 8.3 0.27 c 
Phenytoin 8.3 j 2.5 
Quinidine 8.56 3.4 c 
Risperidone 8.8 2.5 
Sertraline 9.16 k 5.1 
Sulpiride 9.12 l 0.57 
Thiopental 7.55 i 2.85 c 
Verapamil 8.9 i 3.7 c 
Zolpidem 6.2 1.2 
a Unless otherwise stated, calculated using ChemAxon; b Stevenson et al. [127]; c Hansch et al. [108];  
d Merck Index [128]; e Ullrich and Rumrich [129]; f Martin et al. [130]; g Streng W.H. [131]; h Tomlinson and 
Hafkenscheid [132]; i Sangster [133]; j McLure et al. [134]; and k Deak et al. [135]; l El Tayer et al. [136]. 
Table S8. Protein binding and metabolic clearance. 
Compounds 
Protein Binding a Metabolic Clearance 
Plasma Brain CSF Human b Rat c 
fuplasma fubrain fuCSF CLplasma (mL/min/kg) CLint, in vivo (mL/min/kg)
Antipyrine 0.98 0.86 1 0.57 0.21 
Benzypenicillin 0.649 2.26 0.998 na na 
Buspirone 0.45 0.137 0.996 17.17 95.34 
Caffeine 0.917 0.697 1 1.67 0.70 
Carbamazepine 0.385 0.17 0.995 0.4 0.37 
Cephalexin 1.05 1.42 1 na na 
Citalopram 0.82 0.437 0.999 4.5 2.50 
Cimetidine 0.529 0.0197 0.997 3.2 2.55 
Daidzen 0.0542 0.0828 0.95 na na 
Dantrolene 0.117 0.0746 0.978 na na 
Diazepam 0.211 0.0426 0.989 0.51 0.88 
Flavopiridol 0.254 0.0552 0.991 2.1 3.27 d 
Fleroxacin 0.793 0.555 0.999 na na 
Genistein 0.0101 0.0531 0.773 na na 
Loperamide 0.0701 0.00196 0.962 0.1775 0.90 
Midalzolam 0.045 0.0431 0.94 6.5 75.66 
Pefloxacin 0.86 0.514 1 na na 
Phenytoin 0.302 0.0967 0.993 0.47 0.56 
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Table S8. Cont. 
Compounds 
Protein Binding a Metabolic Clearance 
Plasma Brain CSF Human b Rat c 
fuplasma fubrain fuCSF CLplasma (mL/min/kg) CLint, in vivo (mL/min/kg) 
Quinidine 0.454 0.0242 0.996 4.02 3.92 
Risperidone 0.158 0.0596 0.984 5.4 16.55 
Sertraline 0.0347 0.00038 0.923 27.5 158.01 e 
Sulpiride 0.88 0.345 1 0.08 0.03 f 
Thiopental 0.202 0.244 0.988 na na 
Verapamil 0.101 0.0165 0.974 13.3 138.68 
Zolpidem 0.267 0.265 0.992 4.3 7.47 
a Taken from Kodaira et al. [53]; b unless otherwise indicated data was taken from Hallifax et al. [113], as 
either plasma clearance (denoted by: p) or microsomal clearance (denoted by: m); c unless otherwise 
indicated, intrinsic in vivo clearance was calculated based on a well stirrer liver model assuming average 
hepatic blood flow (QH, 55 mL/min/kg). Blood clearance and unbound fraction in blood were determined 
using the blood:plasma ratio (Rb) or by assuming a value of 1 for basic and neutral drugs and 0.55 for  
acidic drugs; d taken from Blum et al. [137]; e calculated from Ronfield et al. [138]; and f taken from  
Bres et al. [139]; na: not applicable. 
Table S9. Renal clearance. Renal clearance in rats (CLR) was calculated based on 
glomerular filtration rate (GFR) ratio approach as described by Lin [70]. 
Compounds Human Rat 
CLR (mL/min/kg) CLR (mL/min/kg) 
Antipyrine 0.038 a 0.11 
Benzypenicillin 3.52 b 10.22 
Buspirone na na 
Caffeine 0.0073 c 0.021 
Carbamazepine na na 
Cephalexin 2.85 d 8.28 
Citalopram na na 
Cimetidine 4.34 e 12.6 
Daidzen na na 
Dantrolene na na 
Diazepam na na 
Flavopiridol na na 
Fleroxacin 0.93 f 2.7 
Genistein na 109 g 
Loperamide na na 
Midalzolam na na 
Pefloxacin na na 
Phenytoin na na 
Quinidine 0.8 h 2.32 
Risperidone na na 
Sertraline na na 
Sulpiride 1.72 i 4.99 
Thiopental na na 
Verapamil na na 
Zolpidem na na 
a Taken from Scavone et al. (1989 [140], 1997 [141]) and Thompson et al. [142]; b taken from Rumble et al. [143]; 
c taken from Birkett and Miners [144]; d taken from Brogard et al. [145]; e taken from Larson et al. [146];  
f taken from Stuck et al. [147]; g taken from Setchell et al. [148]; h taken from Hughes, Ilett and Jellett [149] 
and Verme et al. [150]; and i taken from Bres and Bressolle [140]. 
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S5. Rat Brain PBPK Model Predictions 
Table S10. Model predictions. 
Compounds Transporter Kpuu,brain 
a CSFu:Plasmau b 
Predicted Observed Fold error Predicted Observed Fold error 
Antipyrine  0.235 0.708 3.0 0.215 0.99 4.6 
Benzypenicillin  0.054 0.0264 2.0 0.078 0.0134 5.8 
Buspirone  0.254 0.612 2.4 0.867 0.558 1.6 
Caffeine  0.220 0.584 2.7 0.477 1.03 2.2 
Carbamazepine  0.241 0.771 3.2 0.135 0.535 4.0 
Cephalexin  0.078 0.016 4.8 0.106 0.0225 4.7 
Citalopram  0.045 0.00981 4.6 0.088 0.0211 4.1 
Cimetidine BCRP 0.320 0.494 1.5 0.224 0.667 3.0 
Daidzen BCRP 0.120 0.0667 1.8 0.134 0.189 1.4 
Dantrolene BCRP 0.144 0.0297 4.8 0.037 0.0838 2.3 
Diazepam  0.578 0.805 1.4 0.570 0.847 1.5 
Flavopiridol P-gp 0.087 0.0525 1.7 0.120 0.216 1.8 
Flavopiridol BCRP 0.079 0.0525 1.9 0.098 0.216 2.2 
Fleroxacin BCRP 0.187 0.25 1.3 0.172 0.283 1.6 
Genistein BCRP 0.33 0.181 1.8 0.942 0.589 1.6 
Loperamide P-gp 0.066 0.00886 7.4 0.118 0.0376 3.1 
Midalzolam  0.699 2.19 3.1 0.504 1.35 2.7 
Pefloxacin P-gp 0.154 0.199 1.3 0.196 0.389 2 
Pefloxacin BCRP 0.181 0.199 1.1 0.177 0.389 2.2 
Phenytoin  0.319 0.447 1.4 0.489 0.396 1.2 
Quinidine P-gp 0.176 0.026 6.8 0.054 0.0911 1.7 
Risperidone P-gp 0.10 0.0787 1.2 0.112 0.124 1.1 
Sertraline  0.54 1.85 3.4 0.354 0.832 2.3 
Sulpiride  0.07 0.0219 3.4 0.110 0.0499 2.2 
Thiopental  0.42 0.911 2.2 0.399 0.599 1.5 
Verapamil P-gp 0.24 0.0786 3.1 0.165 0.333 2 
Zolpidem  0.27 0.447 1.7 0.315 0.475 1.5 
a,b Bold indicates parameters predicted with a fold-error >5. 
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Figure S2. LOESS regression and confidence interval plots. 
 
S6. Simulated Kpuu,brain and CSFu:Pu for Loperamide and Quinidine  
Figure S3. Kpuu,brain model predictions for loperamide and quinidine (highlighted in black) 
using an in vivo surrogate efflux ratio metric for highly effluxed transporter substrates. 
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